Recombinant Anti-CD3 x Anti-CLEC12A Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD3 and anti-CLEC12A IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Myelodysplastic syndromes (MDS); Chronic myelogenous leukemia (CML) therapy.
There are currently no customer reviews or questions for Recombinant Human Anti-CD3 x Human Anti-CLEC12A Bispecific Antibody (scIgG) (SCIGG-H249). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS